Free Trial

Fresenius SE & Co. KGaA Q2 2024 Earnings Report

Fresenius SE & Co. KGaA logo
$8.66 -0.16 (-1.81%)
(As of 12/20/2024 05:55 PM ET)

Fresenius SE & Co. KGaA EPS Results

Actual EPS
$0.22
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fresenius SE & Co. KGaA Revenue Results

Actual Revenue
$5.83 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fresenius SE & Co. KGaA Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Fresenius SE & Co. KGaA Earnings Headlines

Jefferies Sticks to Its Buy Rating for Fresenius SE & Co. KGaA (0OO9)
Fresenius SE & Co. KGaA (0OO9) Receives a Buy from J.P. Morgan
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
Fresenius SE & Co. KGaA (0OO9) Gets a Buy from UBS
Warburg Research Remains a Buy on Fresenius SE & Co. KGaA (0OO9)
See More Fresenius SE & Co. KGaA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co. KGaA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. KGaA and other key companies, straight to your email.

About Fresenius SE & Co. KGaA

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY), a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients. This segment offers I.V. generic drugs; biosimilar drugs for autoimmune diseases and oncology; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment provides clinical and nursing care facilities. The Fresenius Vamed segment provides services for hospitals and other healthcare facilities. This segment also offers operational management of healthcare facilities and provides services to patients. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

View Fresenius SE & Co. KGaA Profile

More Earnings Resources from MarketBeat

Upcoming Earnings